Category Archives: Stem Cell Medicine


DIABETES RESEARCH INSTITUTE FOUNDATION RECEIVES $3 MILLION GIFT FROM NORTH AMERICA’S BUILDING TRADES UNIONS TO FUND CELL THERAPY FOR COVID-19 -…

Miami, Fla., May 06, 2020 (GLOBE NEWSWIRE) -- The Diabetes Research Institute Foundation (DRIF) today announced a donation of $3 million from North Americas Building Trades Unions (NABTU), to support specific and urgent research on the use of umbilical cord mesenchymal stem cells to treat COVID-19-related inflammation. The generous gift will accelerate needed clinical trials during this challenging time.

On April 5, 2020, the U.S. Food and Drug Administration (FDA) approved mesenchymal stem cell treatments for seriously ill COVID-19 patients as an expanded access compassionate use. Subsequently, Dr. Camillo Ricordi, Director of the Diabetes Research Institute and Cell Transplant Program, opened the first-of-its-kind clinical trial on the use of umbilical cord mesenchymal stem cells (UC-MSC) to treat COVID-19-related inflammation. The critical study will assess the safety and efficacyincluding clinical outcomes and a variety of pulmonary, biochemical, and immunological testsof the intravenous administration of UC-MSCs in patients with severe cases of COVID-19.

NABTU and its members are proud to stand behind the work of Dr. Ricordi, the Diabetes Research Institute team and their partners around the world as they work to find a cure for diabetes and protect the lives of people affected by COVID-19, said NABTU President Sean McGarvey. As COVID-19 cases show severe implications for high-risk individuals and essential workers, Dr. Ricordis DRI research is essential to treating patients who are facing this life-threatening virus. Our work doesnt stop with this $3 million commitment; NABTU and our members have already begun organizing friends and supporters to raise the $30 million Dr. Ricordi says is required to effectively treat the millions of people who need it and will receive it at no cost to them or their families.

For 35 years, North Americas Building Trades Unions membership has supported the Diabetes Research Institute Foundation, and that longstanding commitment has had a significant impact on our quest for a cure for diabetes, said DRI Foundation CEO Sean Kramer. The continued generosity of NABTUs members over the years has helped fund and develop many clinical trials, including the DRIs prior research on UC-MSCs in patients with type 1 diabetes, but todays gift will truly help all Americans in the midst of this pandemic.

As it has been for decades, whenever we need them, the building trades stand in the breach for their countries and communities, Dr. Ricordi said. This generous donation is another example of how this amazing organization leads by example and how leadership and action can make a difference on the path of cures.

The relationship between DRIF and NABTU began with the Blueprint for Cure in 1984, an unprecedented campaign that supported funding of a state-of-the-art center where scientists would have every tool necessary to conduct research to find a cure for diabetes, a disease afflicting many union members and citizens in North America. Through this initiative, the members of the unions funded and built the Diabetes Research Institute facility in Miami, the most comprehensive diabetes research center in the world. Today, NABTU and its members have donated nearly $60 million to support the DRIFs efforts to find a cure for diabetes.

The DRIF is grateful for NABTUs dedication to our mission and cause, and we are especially appreciative of todays gift, Kramer added. Simultaneously, a therapy for COVID-19 and a cure for type one diabetes are within reach.

To learn more about the DRI mission and research for a cure, visit DiabetesResearch.org.

About the Diabetes Research Institute and Foundation

The mission of the Diabetes Research Institute Foundation is to provide the Diabetes Research Institute with the funding necessary to cure diabetes now. The Diabetes Research Institute at the University of Miami Miller School of Medicine leads the world in cure-focused research. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production in people living with the disease. Researchers have already shown that transplanted islet cells allow patients to live without the need for insulin therapy. Some study participants have maintained insulin independence for more than 10 years. The DRI is now building upon these promising outcomes through its BioHub strategy, a multi-pronged approach that addresses the major challenges standing in the way of a cure. For more information, please visit DiabetesResearch.org or call 800-321-3437.

About NABTU

North Americas Building Trades Unions is an alliance of 14 national and international unions in the building and construction industry that collectively represent over 3 million skilled craft professionals in the United States and Canada. Each year, our unions and our signatory contractor partners invest over $1.6 billion in private-sector money to fund and operate over 1,900 apprenticeship training and education facilities across North America that produce the safest, most highly trained, and productive, skilled craft workers found anywhere in the world. NABTU is dedicated to creating economic security and employment opportunities for its construction workers by safeguarding wage and benefits standards, promoting responsible private capital investments, investing in renowned apprenticeship and training, and creating pathways to the middle class for women, communities of color and military veterans in the construction industry. For more information, please visit http://www.nabtu.org, and to learn more about the building trades efforts during this pandemic, please follow the hashtag #buildingtradeswhateverittakes.

###

See the rest here:
DIABETES RESEARCH INSTITUTE FOUNDATION RECEIVES $3 MILLION GIFT FROM NORTH AMERICA'S BUILDING TRADES UNIONS TO FUND CELL THERAPY FOR COVID-19 -...

FDA Approves Tabrecta, the First Targeted Drug for Patients with Non-Small Cell Lung Cancer and MET exon 14 – Curetoday.com

Tabrecta (capmatinib) will treat patients with metastatic non-small cell lung cancer that has a mutation leading to MET exon 14 skipping. The drug is the first targeted option for patients with lung cancer and this type of mutation.

Tabrecta is the first therapy approved by the FDA specifically to treat NSCLC with mutations that lead to epithelial-mesenchymal transition (EMT), which is MET exon 14 skipping.

Tabrecta is approved for patients who are new to treatment and also those who have received previous therapies, regardless of prior treatment type.

Along with the drug approval, the FDA gave the green light to a companion diagnostic, the FoundationOne CDx assay, which can identify these mutations in patients.

In epithelialmesenchymal transition(EMT), the cells that line an organ lose their polarity and ability to adhere to other cells, giving them the ability to invade tissues and organs. MET exon 14 skipping means that a segment of RNA that should prompt the production of a specific protein stops sending those messages.

The spread of cancer consists of a sequential series of events and MET exon 14 skipping is recognized as a critical event in this process, the FDA stated in a press release about the approval. Mutations leading to MET exon 14 skipping are found in 3% to 4% of patients with lung cancer, the agency stated.

Lung cancer is increasingly being divided into multiple subsets of molecularly defined populations with drugs being developed to target these specific groups, said Dr. Richard Pazdur, director of the FDAs Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDAs Center for Drug Evaluation and Research, in the release.

Taken orally, Tabrecta works by blocking a key protein that drives metastatic NSCLC in these patients. The FDA approved it based on the results of a clinical trial involving patients with NSCLC who had mutations leading to MET exon 14 skipping; their tumors did not express the proteins EGFR or ALK.

The evaluated study population included 28 patients who had never undergone treatment for NSCLC and 69 previously treated patients. The overall response rate (ORR; the percentage of participants who experienced a prespecified amount of tumor shrinkage) for the 28 participants was 68%, with 4% having a complete response and 64% having a partial response.

The ORR for the 69 participants was 41%, with all having a partial response. Of the responding participants who had never undergone treatment for NSCLC, 47% had a duration of response lasting 12 months or longer compared with 32.1% of the responding participants who had been previously treated.

Common side effects for patients taking Tabrecta included swelling of the legs, nausea, fatigue, vomiting, shortness of breath and decreased appetite.

Tabrecta may cause serious side effects including scarring or inflammation of the lungs. It may also cause damage to liver cells or harm a developing fetus or newborn baby. Patients may be more sensitive to sunlight when they take Tabrecta and should take precautions to cover their skin and use sunscreen.

Tabrecta was approved under theFDAs accelerated approval, breakthrough designation and priority review programs, which provide for a quicker review of drugs that treat serious or life-threatening diseases and represent a meaningful advantage over existing treatments.

Continued approval for this indication may be contingent upon verification of these results in confirmatory clinical trials.

Check back for what you need to know regarding this approval.

Read more:
FDA Approves Tabrecta, the First Targeted Drug for Patients with Non-Small Cell Lung Cancer and MET exon 14 - Curetoday.com

UAE stem cell therapy: Revolutionary treatment helps cure COVID-19 patients – Gulf News

Members of the research team at the Abu Dhabi Stem Cell Center, United Arab Emirates. Image Credit: WAM / Gulf News

DUBAI: Adult stem cell therapy is dubbed as the new healing force of the 21st century, much as theinternet revolutionised the past century.

Now, UAE researchers have demonstrated they're in the leading edge of this breakthrough in medicine. Abu Dhabi-based doctors have announced pioneering work in stem cell therapy to repair lung damage caused by coronavirus infection. One simple yet fascinating aspect of this new therapy: it's administered through inhalation.

It's a potential "wow" moment for immunotherapy and regenerative medicine the Abu Dhabi team sucessfully treated73 COVID-19 patients, who were cured of COVID-19 before hospital discharge.

Numerous vaccine trials are undeway for COVID-19, but a safe and effective jab that can be used on a massive scale on healthy patientsis at least a year away.

'National achievement'

Speaking at a press conference on coronavirus updates on Saturday night, Dr. Fatima Al Kaabi, Head Hematologyand ncology Department at Sheikh Khalifa Medical City in Abu Dhabi, explained the results of the stem cell therapy.

At the Abu Dhabi Stem Cell Center, we are proud to work on developing a supportive treatment for COVID-19 patients which is undergoing clinical trials for the first time in the UAE. This is a national achievement, Dr. Fatima Al Kaabi, who is part of the stem cell research team against COVID-19.

The announced treatment is supportive and not curative, she explained, and helps alleviate COVID-19 symptoms rather than eradicating the virus itself.

How many COVID-19 patients were treated with UAE stem cell therapy?

Treatment was administered on 73 confirmed positive COVID-19 patients, and was considered a success, after they were cured of the virus by inhaling the treatment into their lungs after it has been "nebulised into a fine mist".

- Abu Dhabi stem cell therapy team

The pioneeringtreatment is hypothesised to have its therapeutic effect by regenerating lung cells and modulating the immune response to keep it from overreacting to the COVID-19 infection and causing further damage to healthy cells.

73 COVID-19 patients in the UAE who have all been successfully treated -- and cured -- of the virus by inhaling the treatment into their lungs after it has been nebulised into a fine mist.

Who developed the stem cell therapy in the UAE?

The treatment was developed by a team of doctors and researchers at the Abu Dhabi Stem Cell Center (ADSCC).

A patent has been granted by the UAE Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells.

How does stem cell therapy work?

It involves extracting stem cells from the patients own blood and reintroducing them after "activating" them.

The treatment has successfully undergone the initial phase of clinical trials, demonstrating its safety.

IMMUNOTHERAPY: WHAT IS IT?

IMMUNOTHERAPY OR BIOLOGICAL THERAPY: The treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as "activation immunotherapies". immunotherapies that reduce or suppress are classified as "suppression immunotherapies".

Were there any adverse effects in the Abu Dhabi COVID-19 therapy?

None of the patients who had received the treatment reported adverse effects, according to the Abu Dhabi research team.

More importantly, there have been no interactions found with the conventional treatment protocols for COVID-19 patients.

ROLE OF STEM CELLS IN REGENERATIVE MEDICINE

So, cell therapy and tissue engineering are parts of the field of regenerative medicine, whose aim is production of safe and effective therapies.

Stem cells present in almost every type of tissues and represent an endogenous system of regeneration and repair. Therefore, stem cells represent great hope for the future of translational medicine.

[International Journal of Stem Cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961101/%5D

What is a stem cell?

A stem cell is a cell with the unique ability to develop into specialised cell types in the body. It's the basic building block of life.

In the future, they may be used to replace cells and tissues that have been damaged or lost due to disease.

They can become cells of the blood, heart, lungs or other body parts. Stem cells also have a strong secretory function, promoting the formation of new blood vessels, cell proliferation and differentiation and inhibiting inflammatory response, experts say.

TWO MAIN CATEGORIES OF STEM CELLS

A large variety of cell types has been used for regenerative medicine, including adult cells, resident tissue specific stem cells, bone marrow stem cells, Umbilical cord blood stem cells, embryonic stem cells and the recent breakthrough discovery of induced pluripotent stem cells from mature/adult cells (iPS) (called reprogramming, induced a pluripotent state in a previously differentiated cell type). [Source: https://www.ncbi.nlm.nih.gov/pubmed/19376801%5D

How does stem cell therapy work in general?

Stem cells can self-renew or multiply while maintaining the potential to develop into other types of cells.

For example, right now, your body's stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells.

Does inhalation of stem cells actually work in repairing lung tissue?

Yes. At least two studies had demonstratedthis.

The airway epithelium is exposed to inhaled particles and pathogens that may lead to the development of a many infectious and inflammatory respiratory diseases. The study investigated promising stem cell therapy to treat lung and tracheal tissue damage.

The second recent study we found, published onNature Communications on February 28, 2020, shows that an inhalation treatment of secretome and exosome exhibited therapeutic potential for lung regeneration.

These were based on two experimental models of pulmonary fibrosis (lung disease in which persistent injury results in scar tissue formation as fibrosis thickens, the lung tissue loses the ability to facilitate gas exchange and provide cells with needed oxygen).

SARS-CoV-2 is a newly-discoveredpathogen that primarily attacks the lungs (and airway epithelium). This leads to the development of an infectious and inflammatory respiratory disease, called COVID-19, partly as a result of theover-reaction of the human immune system which then leads to acute pneumonia and can be deadly.

SECRETOME AND EXOSOME

Secretome: The stem cell secretome produce tiny communication vesicles (paracrine soluble factors) that interact with surrounding (stem) cells. Healthy Mesenchymal Stem Cells do this intensively with signals that have almost exclusively positive effects on surrounding cells and hence change not only the local tissue environment but also the whole immune system. The properties of the secreted factors are anti-inflammatory, neuro- and angio-trophic, immune modulatory, anti-apoptotic, neuroprotective and anti-oxidatory.[Sources: https://bit.ly/2YnEBqp; https://bit.ly/2WnyfEI%5D

Where was the first research onstem cell therapy against COVID-19 conducted?

How many patients were involved in Chinese stem cellclinical trial?

Four COVID-19 patients who received stem cell treatment while in a serious condition have been reportedly discharged from hospital following recovery. The Chinese researchers said they will expand the clinical trial of the therapy.

Has stem cell therapy been used to treat infectious diseases in the past?

Yes. Stem cell therapy has been used in the treatment of some infectious diseases and complications. For instance, it has been tried in treating H7N9 avian flu and showed good results.

According to the Ministry of Science and Technology, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration. Approvals by the ethics committee, and clinical observation and evaluation are in progress.

What's next?

More trials to demonstrate the efficacy of the treatment are ongoing and are expected to be completed "in a couple of weeks".

The treatment has been given to patients along with the conventional medical intervention and will continue to be applied as an adjunct to established treatment protocols rather than as a replacement.

A UAE patent was granted for the innovative method in which the stem cells are collected, or "harvested".

The innovation represents a pay-off from numerous scientific research work being conducted in the UAE and laws enacted to attract talent from different parts of the world. It also promises to potentially turn the tide in the global effort to fight SARS-CoV-2.

The rest is here:
UAE stem cell therapy: Revolutionary treatment helps cure COVID-19 patients - Gulf News

Institute for Stem Cell Science and Regenerative Medicine …

Institute for Stem Cell Science and Regenerative Medicine (inStem) is an autonomous research institute in Bangalore, dedicated to the study of stem cell science and regenerative medicine research. inStem is funded by Department of Biotechnology and well-supported, with access to facilities at both National Centre for Biological Sciences (NCBS) and Centre for Cellular and Molecular Platforms (C-CAMP).[1] Together these three institutions serve as part of the Bangalore Bio-Cluster.[2] The institute is also the umbrella organization for three initiatives: inStem itself, the Center for Stem Cell Research (CSCR) located at CMC Vellore, and an Extramural Program in Stem Cell Research (EPiSTEM), a funding initiative for support of stem cell research nationwide.[3]Institute for Stem Cell Science and Regenerative Medicine (inStem) is an autonomous research institute in Bangalore, dedicated to the study of stem cell science and regenerative medicine research. inStem is funded by Department of Biotechnology and well-supported, with access to facilities at both National Centre for Biological Sciences (NCBS) and Centre for Cellular and Molecular Platforms (C-CAMP).[1] Together these three institutions serve as part of the Bangalore Bio-Cluster.[2] The institute is also the umbrella organization for three initiatives: inStem itself, the Center for Stem Cell Research (CSCR) located at CMC Vellore, and an Extramural Program in Stem Cell Research (EPiSTEM), a funding initiative for support of stem cell research nationwide.[3]

Read more here:
Institute for Stem Cell Science and Regenerative Medicine ...

Organoids: Exploring Liver Cancer Initiation and the Possibilities of Personalized Glioblastoma Treatment – Technology Networks

In the search for improved and high-throughput in vitro models, organoids have emerged as a promising 3D cell culture technology.1 Defined as a three-dimensional multicellular in vitro tissue construct, organoids are derived from cells that spontaneously self-organize into properly differentiated functional cell types to mimic at least some function of an organ.2 Organoid formation is driven by signaling cues in the extracellular matrix and medium, and is influenced by the particular cell types that are present.2 Compared with two-dimensional cultures, organoids incorporate more physiologically relevant cell-cell and cell-matrix interactions, and are a better reflection of the complex network found in vivo.With significant opportunities for studies of human-specific disease mechanisms, personalized medicine, drug discovery, pharmacokinetic profiling and regenerative medicine, organoids are being pursued across a range of disciplines. Many anticipate that these cell culture models will result in more efficient translation of research into clinical success. In this article, we explore the various types of organoids under development and shine a spotlight on some of the different approaches to organoids in cancer research.

Organoids can be derived from pluripotent stem cells (including embryonic stem cells or induced pluripotent stem cells) or neonatal or adult stem cells from healthy or diseased tissue.1,2 Cancer organoids have been generated from a range of human cancer tissues and cell lines including colon, pancreas, prostate, liver, breast, bladder and lung.6-12 This year, a research group led by Hongjun Song, Professor of Neuroscience at the Perelman School of Medicine at the University of Pennsylvania, published a report in Cell detailing methods for the rapid generation of patient-derived glioblastoma organoids.13Fresh tumor specimens were removed from 53 patient cases to produce microdissected tumor pieces that could survive, develop a spherical morphology and continuously grow in culture for at least two weeks (Figure 1). The production of glioblastoma organoids was achieved while maintaining a high level of similarity between the organoids and their parental tumors, with the expression levels of specific markers showing stability over long-term culture (48 weeks). Importantly, native cell-cell interactions were preserved by avoiding mechanical and enzymatic single-cell dissociation of the resected tumor. As Song explains, this was achieved on a clinically relevant timescale: Normally, the treatment for glioblastoma patients starts one month after surgery. The idea is that glioblastoma organoids can be generated within two weeks and subjected to testing of different treatment strategies to come up with the best option for a personalized treatment strategy.

Figure 1: Glioblastoma organoid generation, from fresh tumor pieces to frozen spherical organoids. Image used with permission from Jacob et al. 2020.One concern with organoid formation and expansion is the potential variability of the serum or Matrigel that can exist across batches and sources, creating variable exogenous factors that could cause the organoid to divert. This ultimately compromises reproducibility, a major bottleneck of current organoid systems.2,13 To avoid this source of error, Songs group used an optimized and defined medium devoid of variable factors that could contribute to the clonal selection of specific cell populations in culture.Glioblastoma is the most prevalent primary malignant brain tumor in adults,14 and having glioblastoma organoids available for research would present significant opportunities, explains Song: They can be used to test different drugs based on mutation profiles and to investigate mechanisms underlying tumor progression, drug sensitivity and resistance. While the accuracy of these predictions would need to be verified, researchers hope that patient-derived organoids will be used to help inform oncologists, accelerate drug discovery, and lead to better clinical trial design.Live-Cell Monitoring: Optimizing Workflows for Advanced Cell Models

As cell-based assays become technically more complex, the need to holistically capture dynamic and sometimes subtle cellular events becomes ever more important. By providing real-time imaging data of cellular events without disturbing the sample during the cell culture workflow, live-cell monitoring can support the optimization of these advanced models. Download this whitepaper to discover how live-cell monitoring can support such optimization, with a breadth of applications.

Sponsored Content

For this to be achieved, techniques for the culture and genetic manipulation of primary human hepatocytes need to be refined. This has mostly been pursued through the culture of liver progenitors or fetal hepatocytes, which facilitate studies of liver cancers related to stem cells.16-18 To address the need for organoids derived from functional hepatocytes, researchers across 14 universities, research institutes and hospitals in China and Japan collaborated to genetically engineer reprogrammed human hepatocytes.18 The study, published in Nature Cell Biology, details the successful generation of organoids that represented two major types of liver cancer (hepatocellular carcinoma: HCC and intra-hepatic cholangiocarcinoma: ICC), derived from directly reprogrammed human hepatocytes (hiHeps).Lead author Lulu Sun, of the Shanghai Institute of Biochemistry and Cell Biology at the University of Chinese Academy of Sciences, provides an overview of how the liver cancer organoids were developed: Genomic aberrations begin to occur during cancer initiation, and the normal cells gradually became malignant. We modeled this process by introducing HCC/ICC-related oncogenes into the organoids with a lentivirus. Oncogenes were selected based on their mutation frequency and previous results in animals. Sun notes that gradual changes in cell and organoid morphology were observed in vitro, along with changes in the expression of HCC-related markers, before the organoids were transplanted to inspect their malignancy in vivo: We cultured these organoids in vitro for about two weeks and transplanted them into the liver lobule of immunodeficient mice. Six to eight weeks later, they formed features identical to HCCs.Even though numerous oncogenes have been identified through whole genome sequencing, it has been difficult to determine whether they can drive the initiation of human liver cancers. Ultrastructural analyses revealed that c-Myc, a well-known oncogene, induced HCC-initiation and a unique cellular phenotype in the hiHep organoids. In these cells, mitochondria were in unusually close contact with endoplasmic reticulum membranes. This excessive coupling between mitochondria and the endoplasmic reticulum (referred to as a MAM phenotype) was shown to facilitate HCC-initiation and when blocked, prevented the progression towards HCC, says Sun: Not only were the expression levels of HCC-related genes in organoids reduced, but significantly reduced cancers were formed in mice.Resolving these alterations in mitochondrial organization represents a new potential approach to liver cancer therapies, and possibly others, Sun explains: Restoration of a proper MAM interface may be a useful approach in preventing c-MYC-initiated HCCs. In addition, recently, an increasing number of works captured ultrastructural alterations, including MAMs, in the course of diseases including Alzheimer's disease and fatty liver diseases. Our results showed that the alterations between communications of organelles may also contribute to the cancer initiation process.All About Organoids

Organoids are 3D cell clusters with the structural and functional features of an organ, and can be generated from induced pluripotent stem cells (iPSCs) or adult stem cells acquired from a specific patient. Consequently, organoids make it possible to study the impact of a drug on a specific disease, even a persons own disease they are changing the face of research and medicine as we know it. Download this eBook to discover more about organoids including their analysis and how they are effecting personalized medicine.

Sponsored Content

2. Huch, M., Knoblich, J. A., Lutolf, M. P, et al. (2017). The hope and the hype of organoid research. Development, 144(6), 938941. https://doi.org/10.1242/dev.150201

3. Hutchinson, L., & Kirk, R. (2011). High drug attrition ratesWhere are we going wrong? Nature Reviews Clinical Oncology, 8(4), 189190. https://doi.org/10.1038/nrclinonc.2011.34

4. Fan, H., Demirci, U., Chen, P. (2019). Emerging organoid models: Leaping forward in cancer research. Journal of Hematology & Oncology, 12(142). https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0832-4

5. Drost, J., Clevers, H. (2018). Organoids in cancer research. Nature Reviews Cancer, 18(7), 407418. https://doi.org/10.1038/s41568-018-0007-6

6. van de Wetering, M., Francies, H. E., Francis, J. M., et al. (2015). Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 161(4), 933945. https://doi.org/10.1016/j.cell.2015.03.053

7. Boj, S. F., Hwang, C.-I., Baker, L. A., et al. (2015). Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 160(12), 324338. https://doi.org/10.1016/j.cell.2014.12.021

8. Puca, L., Bareja, R., Prandi, D., et al. (2018). Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 9(1), 2404. https://doi.org/10.1038/s41467-018-04495-z

9. Broutier, L., Mastrogiovanni, G., Verstegen, M. M., et al. (2017). Human primary liver cancerderived organoid cultures for disease modeling and drug screening. Nature Medicine, 23(12), 14241435. https://doi.org/10.1038/nm.4438

10. Sachs, N., de Ligt, J., Kopper, O., et al. (2018). A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell, 172(12), 373-386.e10. https://doi.org/10.1016/j.cell.2017.11.010

11. Lee, S. H., Hu, W., Matulay, J. T., et al. (2018). Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 173(2), 515-528.e17. https://doi.org/10.1016/j.cell.2018.03.017

12. Kim, M., Mun, H., Sung, C. O., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications, 10(1), 3991. https://doi.org/10.1038/s41467-019-11867-6

13. Jacob, F., Salinas, R. D., Zhang, D. Y., et al. (2020). A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell, 180(1), 188-204.e22. https://doi.org/10.1016/j.cell.2019.11.03

14. Ostrom, Q. T., Gittleman, H., Truitt, G., et al. (2018). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 20112015. Neuro-Oncology, 20(suppl_4), iv1iv86. https://doi.org/10.1093/neuonc/noy131

15. Bruix, J., Han, K.-H., Gores, G., et al. (2015). Liver cancer: Approaching a personalized care. Journal of Hepatology, 62(1), S144S156. https://doi.org/10.1016/j.jhep.2015.02.007

16. Hu, H., Gehart, H., Artegiani, B., et al. (2018). Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids. Cell, 175(6), 1591-1606.e19. https://doi.org/10.1016/j.cell.2018.11.013

17. Zhang, K., Zhang, L., Liu, W., et al. (2018). In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity. Cell Stem Cell, 23(6), 806-819.e4. https://doi.org/10.1016/j.stem.2018.10.018

18. Sun, L., Wang, Y., Cen, J., et al, (2019). Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nature Cell Biology, 21(8), 10151026. https://doi.org/10.1038/s41556-019-0359-5

19. Madhavan, M., Nevin, Z. S., Shick, H. E., et al. (2018). Induction of myelinating oligodendrocytes in human cortical spheroids. Nature Methods, 15(9), 700706. https://doi.org/10.1038/s41592-018-0081-4

20. Post, Y., Puschhof, J., Beumer, J., et al. (2020). Snake Venom Gland Organoids. Cell, 180(2), 233-247.e21. https://doi.org/10.1016/j.cell.2019.11.038

21. Calandrini, C., Schutgens, F., Oka, R., et al. (2020). An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 11(1), 1310. https://doi.org/10.1038/s41467-020-15155-6

22. Subramanian, A., Sidhom, E.-H., Emani, M., et al. (2019). Single cell census of human kidney organoids shows reproducibility and diminished off-target cells after transplantation. Nature Communications, 10(1), 5462. https://doi.org/10.1038/s41467-019-13382-0

Read more:
Organoids: Exploring Liver Cancer Initiation and the Possibilities of Personalized Glioblastoma Treatment - Technology Networks

Scientists from Universities in Russia and Ukraine Collaborate to Research on New Approaches to Treat Obesity and Diabetes – QS WOW News

In the 21st century, the search for methods of treating noncommunicable diseases, such as obesity, metabolic syndrome, and diabetes are amongthe top priorities. Prevention and treatment of these diseases include changing and controlling lifestyle, diet, and the use of pharmaceuticals.

Despite the progress in medicine and pharmacology (developing new solutions for correcting metabolism) and biotechnologies, new effective approaches are still on demand in treating obesity, metabolic syndrome, and diabetes.

Researchers note that adipose tissue is one of the key players in the development of obesity and diabetes. Adipose tissue is classified both by anatomical location and by function (white and brown fat). So, the main functions of white adipose tissue are to save energy in the form of lipids, and it also has an endocrine function the secretion of hormones, growth factors, cytokines, chemokines, etc.

The function of brown adipose tissue is to generate heat during adaptive thermogenesis (the process of generating heat in response to cold stimulation). In humans, unlike rodents (laboratory animals most widely used in medical experiments, including modeling of obesity, metabolic syndrome and diabetes), brown adipose tissue is present in significant numbers only in newborns and infants. Recently, the existence of active thermogenic adipose tissue in adults has been shown, but this adipose tissue differs from classical brown adipose tissue in several aspects (development, morphology, gene expression, adipokine production, etc.). This adipose tissue is called brown.

All types of adipocytes (cells that make up adipose tissue mainly) arise from adipose stem cells during differentiation. Currently, the question of the origin of brown adipocytes (from the same stem cell as white adipocytes, or from the same stem cell as brown adipocytes, or from its own stem cell), as well as the ability of white adipose tissue to differentiate into brown adipose tissue.

The ability to control the formation of new adipose tissue, turn white adipose tissue into brown one, or determine the direction of adipocyte stem cell differentiation into a specific subtype is an attractive goal for the development of new pharmacological substances for the treatment of obesity, metabolic syndrome and diabetes.

In addition to the search for new pharmacological substances designed to control the functions of adipose tissue or various other biochemical aspects of energy homeostasis, it is also important to study the role of water in human health, metabolism and the pathogenesis of various diseases. Water is the most abundant chemical substance on Earth and makes up the largest mass fraction in living organisms as a percentage. Water is also a universal solvent in which the basic biochemical processes of living organisms occur.

An important component of a healthy diet is drinking water instead of sugar and soda. So, the modulation of the biological and physico-chemical properties of water is also a promising opportunity to increase the effectiveness of the treatment of said diseases.

Dr. Larisa Litvinova, Ph.D. in Medicine, Head of the Immunology and Cell Biotechnologies Laboratory says,One of the focuses of modern medicine is the development of deuterium-containing drugs. Another direction relates to the role of the D/H ratio of isotopology and its change in water, which will be used as an adjuvant in the treatment of cancer. A different D/H ratio manifests itself in the form of a kinetic isotope effect, which is characterized by a change in the rates of biotransformation and excretion of drugs. Moreover, methodological approaches to the quality control of medicines based on isotopology of water could reduce the toxic load on the body.

IKBFU Scientists Larisa Litvinova and Maria Wulf were conducting the research in cooperation with colleagues from Moscow and Kiev and the goal of the research was to find out whether deuterium is engaged in the differentiation of adipose tissue stem cells regulation. Adipogenic differentiation of mesenchymal stem cells was chosen as an in vitro model, where the efficiency of the formation of mature fat cells from precursor cells in media with different deuterium contents were evaluated.

The data on the effect of various concentrations of deuterium on the efficiency and direction (formation of brown/beige or white adipocytes) of differentiation of mesenchymal stem cells in an in vitro model system were obtained in the study. Naturally for the possible practical application of these results, additional studies are needed that would allow a more detailed description of the molecular mechanisms of the influence of various concentrations of deuterium at the cellular level, as well as studies at the body level.

The results of the study are published in the article The influence of deuterium on the effectiveness and type of adipogenic differentiation of stem cells of human adipose tissue in vitro in theScientific Reportsjournal.

The results can serve as the basis for the development of new approaches in the treatment of obesity, metabolic syndrome, and diabetes, by regulating the differentiation of fat stem cells and adipocyte functions.

Read the original here:
Scientists from Universities in Russia and Ukraine Collaborate to Research on New Approaches to Treat Obesity and Diabetes - QS WOW News

Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 – BioSpace

DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Companys initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).

DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.1

Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19,said Joseph Lasky, M.D., Professor of Medicine, Pulmonary and Critical Care Section Chief, John W. Deming, M.D. Endowed Chair in Internal Medicine at Tulane University Medical School. Based on the literature, we believe DSTAT has the potential to reduce the excessive inflammation, immune cell infiltration and hypercoagulation associated with poor outcomes in patients with severe COVID-19 infection.

DSTAT is well-suited to unlock the anti-inflammatory properties of heparin as it may be dosed at much higher levels than any available form of heparin without triggering bleeding complications, said Mike Sherman, Chief Executive Officer of Chimerix. We had planned to evaluate DSTAT in several indications of high unmet need, including ALI from different causes. The pandemic intensified our focus on ALI associated with COVID-19. Our team has worked closely with critical care physicians treating COVID-19 patients and with the U.S. Food and Drug Administration (FDA) to develop a Phase 2/3 protocol to determine if DSTAT can reduce the need for mechanical ventilation and improve the rate of survival in patients with severe COVID-19 infection.

Phase 2/3 Study Design

The study is a 1:1 randomized, double-blind, placebo-controlled, Phase 2/3 trial to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at high risk of respiratory failure. Eligible subjects will be those with confirmed COVID-19 who require hospitalization and supplemental oxygen therapy. The primary endpoint of the study is the proportion of subjects who survive and do not require mechanical ventilation through day 28. Additional endpoints include time to improvement as assessed by the National Institute of Allergy and Infectious Disease ordinal scale, time to hospital discharge, time to resolution of fever, number of ventilator-free days, all-cause mortality, and changes in key biomarkers (e.g. interleukin-6 (IL-6), tumor necrosis factor- (TNF-), high mobility group box 1 (HMGB1), C-reactive protein and d-dimer).

The Phase 2 portion of the study will enroll 24 subjects to confirm the maximum safe dose and will then expand by an additional 50 patients (74 total) at the selected dose. A formal analysis of all endpoints, including supportive biomarkers will be performed at the conclusion of the phase 2 portion of the study. Contingent upon positive results, the Phase 3 portion of the study will enroll approximately 450 subjects.

Clinical Rationale for DSTAT in COVID-19 Patients with ALI

The clinical manifestations of COVID-19 range from mild, self-limited respiratory tract illness to severe alveolar damage and progressive respiratory failure, multiple organ failure, and death. Mortality in COVID-19 is associated with severe pulmonary disease and coagulation disorders such as disseminated intravascular coagulation (DIC).2,3

The mechanistic rationale supporting DSTATs potential in ALI patients with COVID-19 is two-fold:

In a recent Phase 2 Acute Myeloid Leukemia (AML) study DSTAT was well tolerated with adverse events similar across DSTAT and control groups. DSTAT is an investigational agent, not yet licensed or approved for use.

Conference Call and Webcast

Chimerix will host a conference call and live audio webcast today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 8263766.

A live audio webcast of the call will also be available on the Investors section of Chimerixs website, http://www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

Dociparstat sodium is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity In vitro and in vivo animal model data support DSTATs potential to reduce the inflammation and cellular infiltration associated with acute lung injury and address coagulation disorders associated with COVID-19 pathology. Separately, DSTAT inhibits the activities of several key proteins implicated in the viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy (e.g., CXCL12, selectins, HMGB1, elastase). Randomized Phase 2 data suggest that DSTAT may also accelerate platelet recovery post-chemotherapy via inhibition of PF4, a negative regulator of platelet production that impairs platelet recovery following chemotherapy. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, http://www.chimerix.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the mechanism of action of DSTAT and its potential in ALI patients with COVID-19; Chimerixs ability to develop DSTAT, including the initiation of a Phase 2/3 clinical trial for DSTAT as a potential treatment for ALI associated with COVID-19; and Chimerixs ability to submit and/or obtain regulatory approvals for DSTAT. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that DSTAT may not achieve the endpoints of the Phase 2/3 clinical trial; risks that DSTAT may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that development activities related to DSTAT may not be completed on time or at all; Chimerixs reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:Investor Relations:Michelle LaSpaluto919 972-7115ir@chimerix.com

Will OConnorStern Investor Relationswill@sternir.com212-362-1200

Media:David SchullRusso Partners858-717-2310david.schull@russopartnersllc.com

note: DSTAT may be referred to as 2-O,3-O desulfated heparin, ODSH or CX-01 in these references.

See original here:
Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 - BioSpace

Cell Culture Protein Surface Coating Market Competitive Analysis and Forecast 2017-2025 – Latest Herald

Global Cell Culture Protein Surface Coating Market: Snapshot

The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering.

Thus, the growing scope of cell cultures in various applications has led to the development of the 3D cell culture technique, which has been considered one of the key factors responsible for the overall past development of the cell culture protein surface coatings market. Earlier, only a meager percentage of researchers preferred using 3D cell culture technique for drug discovery. However, there has been a dynamic shift from the traditional methods to the current cell culture methods.

Moreover, commercial production of drugs and biologics such as proteins, antibodies, and vaccines using cell culture has helped expand the scope of the latter in the global market. Commercial production has provided extensive business opportunities to manufacturers in the global market. Diverse applications of stem cells such as development of bone grafts and artificial tissue are also expected to fuel the demand for cell culture protein surface coatings over the forecast period. In addition, increasing cell culture applications in toxicology studies and cell-based assays are further pushing the growth of the market.

Global Cell Culture Protein Surface Coating Market: Overview

Cell culture protein surface coatings help in improving cell attachment, growth, and differentiation. They facilitate consistent performance in various cell-based assays and in-vitro culture by improving cell adhesion. A variety of adhesion proteins and other biological materials derived from various sources are being used to enhance performance in cell culture, especially in cell lines that are hard to attach, such as transfected cells. The major types of cell culture are animal-derived protein, human-derived protein, synthetic protein, and plant-derived protein. Good cell attachment has gained increased significance in recent years for improving the recovery of cells from frozen cultures and increasing the stability of attached surfaces. With constant advances in stem cell therapies, a number of advanced protein surface coatings have emerged to study stem cells and to further the potential of regenerative medicine. These developments have positively affected the growth of the global cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Key Trends

The increasing focus of numerous biotechnology companies and research laboratories on stem cell research to develop therapies for a range of chronic diseases is a key factor propelling the cell culture protein market. Considerable investment by the governments of various countries to fund several R&D activities related to regenerative medicine has fuelled the market. Coupled with this, the rising demand for biopharmaceutical products such as antibodies, vaccines, and drugs has stimulated the demand for cell culture protein surface coatings. The growing research on stem cells for finding therapies for various cardiovascular and neurological diseases is expected to boost the market in the coming years. The growing prominence of 3D cell culture over 2D cell cultures is expected to unlock exciting opportunities in the cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Market Potential

The American Heart Association (AHA), together with the Paul G. Allen Frontiers Group, announced in April, 2017 two grantseach worth US$1.5 millionto scientists working on cardiovascular extracellular matrix (ECM) research. Interested researchers have to apply for grants by May 10, and each of the two winners will be entitled to the magnanimous sum.

The ECM regulates all vital cell functions and is considered a highly useful biomaterial for investigators. This can be applied as a stable coating to be used in a variety of cell cultures. The initiative focused on investigating the role of ECM in the initiation and progression of a number of cardiovascular diseases, such as hypertensive heart disease, ischemic heart disease, cardiomyopathies, congenital cardiovascular malformations, and atherosclerosis and vascular diseases. The funding will further the investigation into the diagnosis, prevention, and treatment of cardiovascular diseases. One of the most commonly used protein surface coatings used in ECM is collagen, which facilitates cell adherence, growth, migration, differentiation, and proliferation. The major research initiatives, opine the AHA, will be greatly useful in setting up a new paradigm in research in cell structure in biosciences.

Global Cell Culture Protein Surface Coating Market: Regional Outlook

North America is a prominent market for cell culture protein surface coatings and is expected to exhibit significant growth over the forecast period. The impressive growth in the regional market is attributed to the presence of a robust healthcare infrastructure and considerable advances in stem cell research. In addition, the soaring demand for regenerative medicines for a range of autoimmune therapies is expected to fuel the demand for surface coatings for improving the performance of in-vivo culture.

The Asia Pacific market for cell culture protein surface coating is poised to offer lucrative avenues for players in the market. Favorable regulations for biologics development and a burgeoning biotechnology industry are the factors expected to lead to substantial demand for cell culture protein surface coatings.

Global Cell Culture Protein Surface Coating Market: Competitive Analysis

The market is fairly competitive due to the presence of a large number of regional and global vendors. Leading vendors are actively focused on providing solutions having cell attachment ability and promoting in-vitro cell functions for a variety of cell types to gain competitive edge over others. Leading players operating in this market include Sigma-Aldrich Corporation, Agilent Technologies, Thermo Fisher Scientific, EMD Millipore, Corning Incorporated, Biomedtech Laboratories Inc., Neuvitro Corporation, and Progen Biotechnik GmbH.

The rest is here:
Cell Culture Protein Surface Coating Market Competitive Analysis and Forecast 2017-2025 - Latest Herald

Stem Cell Treatment Options | National Stem Cell Clinic

Find The Right Treatment Option Available For You

Dealing with chronic pain might have become routine, but it doesnt have to be your normal anymore. At National Stem Cell Clinic, our doctors have years of experience with regenerative medicine, improving the lives of patients just like you. We treat various areas of the body, including the following:

Degenerative discs often cause chronic neck pain. While surgery is a common solution, we have a less invasive solution with regenerative stem cells. After harvesting stem cells and combining them with growth factors, they are injected directly into the damaged portion of the neck. After about three weeks youll begin to notice results.

Learn more about stem cell therapy for neck pain

Stem cell therapy benefits patients with common shoulder injuries such as dislocations, arthritis, thoracic outlet syndrome, and rotator cuff issues. Unlike full joint replacement or other corrective shoulder surgeries, patients are able to get back to regular activity immediately.

Find out more about stem cell therapy for shoulder pain

Patients who have experienced chronic back pain may have been directed to physical therapy, pain meds, exercise, and other types of therapy. While these treatments assist in improving back function, full restoration rarely takes place. Now, regenerative medicine repairs damaged discs with the recreation of living tissues which are then injected into the damaged portion of the lower back, offering a significantly higher rate of full restoration.

About Our Stem Cell Therapy for Lower Back Pain

Back pain can be a debilitating condition of which people suffer for years on end. Many patients run through a gauntlet of tests and procedures and still find relief to be elusive. Fortunately, with new therapies and technologies, there is hope for sufferers of this chronic condition.

About Our Stem Cell Therapy for Back Pain

While osteoarthritis is a common reason for knee pain, it is often the result of another type of injury. This could include a fracture, a tear in the ligament, a muscle strain, or damage to the tendon. Minimally invasive stem cell injections can help patients suffering from this chronic pain to go from pain to self-recovery in just a few short months.

Learn about our stem cell treatment for knees

Like the knees, a lot of pain in patients is related to osteoarthritis. Individuals report immobility accompanied by painful swelling. Their hips may feel sharp, stabbing pains or dull aches. Other patients have pain caused by a traumatic injury. In either case, stem cell regeneration is a solution in which pain is minimized, tissues are rebuilt, and cartilage cells are replaced. After the procedure, the patients body works to reduce pain and inflammation with the regenerated cells.

Find out more about our stem cell treatments for hips

The elbow is a joint you regularly use, whether youre eating, playing a sport, playing an instrument, or simply using the remote control. If you want to avoid surgery or other invasive treatment options for your elbow pain, regenerative medicine is an option youll appreciate. Patients with golfers elbow, tennis elbow, arthritis, nerve entrapment, and similar elbow issues can get back to normal life immediately following the procedure.

More about our stem cell therapy for elbows

When you want a non-invasive treatment option for issues with your wrist, regenerative stem cells are the way to turn. Patients with trigger finger, instability, TFCC tears, arthritis, and other common wrist conditions can begin to function regularly after their own stem cells are used to repair damaged tissues within the wrist.

Read more about our treatment for wrist pain

When the median nerve in the hand is compressed, patients are often diagnosed with carpal tunnel syndrome. Basic pain, tingling, and numbness are frequently the resulting symptoms, though more severe nerve damage can occur. In any case, patients who are suffering from carpal tunnel can relieve symptoms with stem cell therapies, in which their damage is repaired with living, functional tissues.

Discover our treatment program for carpal tunnel

Your ankles and feet carry a heavy load, so when you begin to feel pain, its important to get treatment right away. Regenerative medicine can be used for ligament sprains, ankle instability, plantar fasciitis, tarsal tunnel syndrome, arthritis, and a variety of other conditions related to the ankle or foot.

More about our ankle and foot pain treatment with stem cells

Regenerative medicine has been found useful for those experiencing hair loss. Doctors reproduce and reintroduce the cells needed to the scalp. The patients previous hair begins to grow, making baldness a thing of the past.

Learn more about treatment for baldness

At National Stem Cell Clinic, we are happy to show you how regenerative medicine can improve your life. Contact us today!

Continue reading here:
Stem Cell Treatment Options | National Stem Cell Clinic

Impact of COVID-19 on Stem Cell Assay Market In-Depth Analysis And Forecast 2020-2027 | By Top Key Players Merck & Co., Thermo Fisher Scientific,…

The Stem Cell Assay Market Has Witnessed Continuous Growth In The Past Few Years And Is Projected To Grow Even Further During The Forecast Period (2020-2027). The Assessment Provides A 360 View And Insights, Outlining The Key Outcomes Of The Industry. These Insights Help The Business Decision-makers To Formulate Better Business Plans And Make Informed Decisions For Improved Profitability. In Addition, The Study Helps Venture Or Private Players In Understanding The Companies More Precisely To Make Better-informed Decisions. Some Of The Prominent Key Players Covered In The Stem Cell Assay Market Are Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

Whats Keeping Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International. Ahead In The Market? Benchmark Yourself With Strategic Steps And Conclusions Recently Published By Coherent Market Insights

Read Detailed Index of full Research Study @ https://www.coherentmarketinsights.com/ongoing-insight/stem-cell-assay-market-1632

Type Segmentation:

By Product Type-InstrumentsReagents & KitsBy Cell Type Adult Stem CellsInduced Pluripotent Stem CellsMesenchymal Stem CellsNeural Stem CellsHematopoietic Stem CellsUmbilical Cord Stem CellsHuman Embryonic Stem CellsBy Process Cell CultureEngineeringDifferentiationCharacterizationOthersBy Application -ResearchDrug Discovery & DevelopmentRegenerative Medicine

Consumer Traits (If Applicable)

The Stem Cell Assay Market Study Covers Current Status, % Share, Future Patterns, Development Rate, Swot Examination, Sales Channels, To Anticipate Growth Scenarios For Years 2020-2027. It Aims To Recommend Analysis Of The Market With Regards To Growth Trends, Prospects, And Players Contribution To Market Development. The Report Size Market By 5 Major Regions, Known As, North America, Europe, Asia Pacific (Includes Asia & Oceania Separately), Middle East And Africa (Mea), And Latin America.

The Stem Cell Assay Market Factors Described In This Report Are:-key Strategic Developments In Stem Cell Assay Market: The Research Includes The Key Strategic Activities Such As R&d Plans, M&a Completed, Agreements, New Launches, Collaborations, Partnerships & (Jv) Joint Ventures, And Regional Growth Of The Key Competitors Operating In The Market At A Global And Regional Scale.

Key Market Features In Stem Cell Assay Market: The Report Highlights Stem Cell Assay Market Features, Including Revenue, Weighted Average Regional Price, Capacity Utilization Rate, Production Rate, Gross Margins, Consumption, Import & Export, Supply & Demand, Cost Bench-marking, Market Share, Cagr, And Gross Margin.

Analytical Market Highlights & Approach The Stem Cell Assay Market Report Provides The Rigorously Studied And Evaluated Data Of The Top Industry Players And Their Scope In The Market By Means Of Several Analytical Tools. The Analytical Tools Such As Porters Five Forces Analysis, Feasibility Study, Swot Analysis, And Roi Analysis Have Been Practiced Reviewing The Growth Of The Key Players Operating In The Market.

Get Request a Sample Copy @https://www.coherentmarketinsights.com/insight/request-sample/1632

Table Of Contents:

Stem Cell Assay Market Study Coverage: It Includes Major Manufacturers, Emerging Players Growth Story, Major Business Segments Of Stem Cell Assay Market, Years Considered, And Research Objectives. Additionally, Segmentation On The Basis Of The Type Of Product, Application, And Technology.

Stem Cell Assay Market Executive Summary: It Gives A Summary Of Overall Studies, Growth Rate, Available Market, Competitive Landscape, Market Drivers, Trends, And Issues, And Macroscopic Indicators.Stem Cell Assay Market Production By Region Stem Cell Assay Market Profile Of Manufacturers-players Are Studied On The Basis Of Swot, Their Products, Production, Value, Financials, And Other Vital Factors.

Key Points Covered In Stem Cell Assay Market Report: Stem Cell Assay Overview, Definition And Classification Market Drivers And Barriers

Stem Cell Assay Market Competition By Manufacturers

Stem Cell Assay Capacity, Production, Revenue (Value) By Region (2019-2027)

Stem Cell Assay Supply (Production), Consumption, Export, Import By Region (2019-2027)

Stem Cell Assay Production, Revenue (Value), Price Trend By Type {strip Sensors, Invasive Sensors, Ingestible Sensors, Implantable Sensors, Wearable Sensors}

Stem Cell Assay Market Analysis By Application {hospitals, Ambulatory Surgical Centers, Diagnostic Centers}

Stem Cell Assay Manufacturers Profiles/analysis Stem Cell Assay Manufacturing Cost Analysis, Industrial/supply Chain Analysis, Sourcing Strategy And Downstream Buyers, Marketing Strategy By Key Manufacturers/players, Connected Distributors/traders Standardization, Regulatory And Collaborative Initiatives, Industry Road Map And Value Chain Market Effect Factors Analysis.

Get Updated PDF Brochure of this Report @https://www.coherentmarketinsights.com/insight/request-pdf/1632

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

See the rest here:
Impact of COVID-19 on Stem Cell Assay Market In-Depth Analysis And Forecast 2020-2027 | By Top Key Players Merck & Co., Thermo Fisher Scientific,...